The Necessity of an ICD-Therapy in Patients with Indications for Primary Prevention of Sudden Cardiac Death. One Center Experience

Aim      Analysis of responses of cardioverter-defibrillators implanted in patients with cardiomyopathies (CMPs) of various origins and a high risk of sudden cardiac death (SCD) to assess the effectiveness of a modern strategy for primary prevention of SCD.

Material and methods  In the Federal Center for High Medical Technologies in Kaliningrad from 2014 through 2018, implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D) were installed in 165 patients. Major indications for device implantation in these patients included left ventricular (LV) systolic dysfunction with ejection fraction (EF) ≤35 %; chronic heart failure (CHF) consistent with the New York Heart Association (NYHA) functional class (FC) II-III (IV for CRT-D) without previous episodes of life-threatening ventricular arrhythmias, circulatory arrest and resuscitation, which was consistent with the current international strategy for primary prevention of SCD. The study patients were divided into two groups based on the CMP origin; group 1 included 101 (61.2 %) patients with CMP of ischemic origin (ICMP) and group 2 consisted of 64 (38.8 %) patients with CMP of non-ischemic origin (NCMP). Information about arrhythmic episodes and device activation was retrieved from the device electronic memory during visits of patients to the clinic and was also transmitted to the clinic by a remote monitoring system. This information was studied and evaluated for the validity and effectiveness of the device triggering. If necessary, the parameters of detection and treatment were adjusted taking into account the obtained information. Information was analyzed and statistically processed with the SPSS Statistics 20.0 software.

Results The patients were followed up for 28.3 ± 15.6 months, during which the devices delivered therapy to 55 (33.3%) patients of the entire group. In the ICMP group, the devices were activated in 44 (26.7 %) patients and in the NCMP group, the devices were activated in 11 (6.7 %) patients. In group 1 (ICMP), appropriate triggering was observed in 33 (20.0%) patients and inappropriate triggering was observed in 11 (6.7%) patients. In group 2 (NCMP), appropriate triggering was observed in 2 (1.2 %) patients and inappropriate triggering was observed in 9 (5.5 %) patients. The main cause of inappropriate triggering was atrial fibrillation (AF). 17 (10.3 %) patients with ICMP had sustained ventricular tachycardia (VT), which did not reach the detection frequency for ICD therapy; these VTs were only detected by devices and terminated spontaneously. Intragroup differences in the number of patients who received an appropriate treatment were statistically significant: 33 (32.6 %) in the ICMP group vs. 2 (3.1 %) in the NCMP group (р<0.006). Differences in the number of patients who received an inappropriate treatment were not statistically significant although their number was greater in the NCMP group than in the ICMP group (9 (14.1 %) vs. 11 (10.9 %), р>0.05).

Conclusion      A higher requirement for the ICD treatment was revealed in patients with ICMP compared to patients with NCMP. The low demand for the ICD treatment in patients with NCMP and the more frequent inappropriate actuation of the devices in this patient group due to AF allow a conclusion that the criteria for primary prevention of SCD with ICD (LV EF ≤35% and clinically significant CHF) are not equally effective indications for ICD implantation in patients with ICMP and NCMP. It can be assumed that life-threatening ventricular arrhythmias are evident in patients with NCMP before the development of hemodynamically significant LV dysfunction and CHF, which warrants further research in this direction.

1. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal. 2015;36(41):2793–867. DOI: 10.1093/eurheartj/ehv316

2. Revishvili A.Sh., Shlyakhto E.V., Popov S.V., Pokushalov E.A., Shkolnikova M.A., Sulimov V.A. et al. Clinical recommendations for electrophysiological studies, catheter ablation and implantable antiarrhythmic devices. -M.: VNOA;2017. - 702 p. ISBN 978-5-9500922-0-6

3. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992;85(1 Suppl):I2-10. PMID: 1728501

4. de Vreede-Swagemakers JJM, Gorgels APM, Dubois-Arbouw WI, van Ree JW, Daemen MJAP, Houben LGE et al. Out-of-Hospital Cardiac Arrest in the 1990s: A Population-Based Study in the Maastricht Area on Incidence, Characteristics and Survival. Journal of the American College of Cardiology. 1997;30(6):1500–5. DOI: 10.1016/S0735-1097(97)00355-0

5. Lyons AS, Petrucelli RJ. Medicine: an illustrated history. -New York: Abradale Press/H.N. Abrams;1987. - 616 p. ISBN 978-0-8109-1054-6

6. de Luna AB, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. American Heart Journal. 1989;117(1):151–9. DOI: 10.1016/0002-8703(89)90670-4

7. Myerburg RJ. Sudden Cardiac Death: Exploring the Limits of Our Knowledge. Journal of Cardiovascular Electrophysiology. 2001;12(3):369–81. DOI: 10.1046/j.1540-8167.2001.00369.x

8. Bokeria L.A., Neminushchiy N.M., Postol A.S. Implantable Cardioverter-Defibrillators are the Main Link in the Modern Concept of Sudden Cardiac Death Prevention. Problems and Prospects of the Development of the Method. Kardiologiia. 2018;58(12):76–84. DOI: 10.18087/cardio.2018.12.10197

9. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. The New England Journal of Medicine. 2004;350(21):2151–8. DOI: 10.1056/NEJMoa033088

10. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E et al. Defibrillator implantation in patients with nonischemic systolic heart failure. New England Journal of Medicine. 2016;375(13):1221–30. DOI: 10.1056/NEJMoa1608029

11. Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K et al. Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453–8. DOI: 10.1161/01.CIR.0000012350.99718.AD

12. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. Journal of the American College of Cardiology. 2003;41(10):1707–12. DOI: 10.1016/S0735-1097(03)00297-3

13. Disertori M, Masè M, Rigoni M, Nollo G, Arbustini E, Ravelli F. Implantable Cardioverter-Defibrillator in Dilated Cardiomyopathy after the DANISH-Trial Lesson. A Poly-Parametric Risk Evaluation Is Needed to Improve the Selection of Patients. Frontiers in Physiology. 2017;8:873. DOI: 10.3389/fphys.2017.00873

14. Wu KC. Sudden Cardiac Death Substrate Imaged by Magnetic Resonance Imaging: From Investigational Tool to Clinical Applications. Circulation: Cardiovascular Imaging. 2017;10(7):e005461. DOI: 10.1161/CIRCIMAGING.116.005461

15. Disertori M, Masè M, Ravelli F. Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends in Cardiovascular Medicine. 2017;27(5):363–72. DOI: 10.1016/j.tcm.2017.01.011

16. Arbustini E, Disertori M, Narula J. Primary Prevention of Sudden Arrhythmic Death in Dilated Cardiomyopathy. JACC: Heart Failure. 2017;5(1):39–43. DOI: 10.1016/j.jchf.2016.11.009

17. Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y et al. Prognostic Value of LGE-CMR in HCM. JACC: Cardiovascular Imaging. 2016;9(12):1392–402. DOI: 10.1016/j.jcmg.2016.02.031

18. Reiter U, Reiter C, Kräuter C, Fuchsjäger M, Reiter G. Cardiac magnetic resonance T1 mapping. Part 2: Diagnostic potential and applications. European Journal of Radiology. 2018;109:235–47. DOI: 10.1016/j.ejrad.2018.10.013

19. Stiles MK, Fauchier L, Morillo CA, Wilkoff BL, ESC Scientific Document Group, Boveda S et al. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. EP Europace. 2019;21(9):1442–3. DOI: 10.1093/europace/euz065

20. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–158. DOI: 10.18087/cardio.2475

21. van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermansvan Ast JF, van der Kooi AJ et al. Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers a European cohort study. Journal of the American College of Cardiology. 2012;59(5):493–500. DOI: 10.1016/j.jacc.2011.08.078

22. Van der Zwaag PA, van Rijsingen IAW, Asimaki A, Jongbloed JDH, van Veldhuisen DJ, Wiesfeld ACP et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. European Journal of Heart Failure. 2012;14(11):1199–207. DOI: 10.1093/eurjhf/hfs119

23. López-Ayala JM, Gómez-Milanés I, Sánchez Muñoz JJ, Ruiz-Espejo F, Ortíz M, González-Carrillo J et al. Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype. EP Europace. 2014;16(12):1838–46. DOI: 10.1093/europace/euu128

24. Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology. 2016;68(22):2440–51. DOI: 10.1016/j.jacc.2016.09.927

25. van den Hoogenhof MMG, Beqqali A, Amin AS, van der Made I, Aufiero S, Khan MAF et al. RBM20 Mutations Induce an Arrhythmogenic Dilated Cardiomyopathy Related to Disturbed Calcium Handling. Circulation. 2018;138(13):1330–42. DOI: 10.1161/CIRCULATIONAHA.117.031947

26. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK et al. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation. 2019;140(4):293–302. DOI: 10.1161/CIRCULATIONAHA.118.039410

27. Haugaa KH, Tilz R, Boveda S, Dobreanu D, Sciaraffia E, Mansourati J et al. Implantable cardioverter defibrillator use for primary prevention in ischaemic and non-ischaemic heart disease – indications in the post-DANISH trial era: results of the European Heart Rhythm Association survey. EP Europace. 2017;19(4):660–4. DOI: 10.1093/europace/eux089